Health TrialsbyHealthPanel

Ex VIvo DEtermiNed Cancer Therapy

ConditionsBladder CancerKidney CancerMelanomaSarcomaGlioblastomaHead and Neck Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16+
SponsorSheffield Teaching Hospitals NHS Foundation Trust

About this trial

EVIDENT's aim is to test if ex vivo drug screening can predict whether patients with solid cancers will respond, or not respond, to standard care treatments. Patients undergoing standard care surgery to excise their tumour, those undergoing a biopsy, or those having a fluid aspirate of a solid tumour with surplus tissue available after diagnostic use will be eligible for this study. The specimen will then be assessed with ex vivo drug screening utilising all standard therapies and therapies that are more novel and in early stages of development. The results of the ex vivo drug screen will be compared to the cancer's actual response to standard care treatments for those that undergo therapy to determine how effective the test is at predicting treatment response.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Present with a recurrence of a previously treated tumour. This may be a local or metastatic recurrence

Have undergone treatment for their cancer, but fail to respond to this and progress

Have received neoadjuvant therapy for their tumour

Have undergone chemotherapy, targeted therapy, immunotherapy, hormone therapy and or radiotherapy for a previous tumour

Disqualifiers

None

Trial population

All participants who fit the eligibility criteria who are currently under the care of Sheffield Teaching Hospitals NHS Foundation Trust

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Functional drug screen

    Diagnostic test

    High-throughput ex-vivo drug screen of cells processed directly from solid tumours to determine sensitivity / resistance profiles

Treatment groups

600 Participants
are divided into 6 treatment groups

6

Treatment groups

See each treatment group below.

Group A: Bladder Cancer1 intervention
Group B: Kidney Cancer1 intervention
Group C: Melanoma1 intervention
Group D: Sarcoma1 intervention
Group E: Glioblastoma1 intervention
Group F: Head and Neck Cancer1 intervention

Trial outcomes

Primary outcomes

1

Functional drug screen

Collect and functionally screen solid tumours to determine if ex-vivo drug screening can predict effectiveness of standard cytotoxic chemotherapies and targeted inhibitors in solid cancers by correlating ex-vivo results with patients actual response to standard care.

Time frame
6 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sheffield Teaching Hospitals NHS Foundation Trust

Lead sponsor

University of Sheffield

Collaborator

Source ClinicalTrials.gov
Apply now